Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
NDA accepted for review in China

September 11, 2026

What is the news ?

Nicox announced that its exclusive licensee in China, Ocumension Therapeutics, received confirmation from China’s National Medical Products Administration that the NCX 470 NDA has been accepted for review.

What does it mean ?

Acceptance initiates the examination process and is another key step towards NCX 470’s commercialisation in China.

What are the next steps ?

While the NMPA does not provide a specific review timeline, regulatory decisions in China typically take approximately 12 to 18 months.
View Press Release Corporate presentation Contact us
Previous